296 filings
8-K
SRPT
Sarepta Therapeutics Inc
8 Jan 24
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
12:08pm
8-K
SRPT
Sarepta Therapeutics Inc
22 Jun 23
Regulation FD Disclosure
4:49pm
8-K
SRPT
Sarepta Therapeutics Inc
22 Jun 23
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
12:00am
8-K
SRPT
Sarepta Therapeutics Inc
9 Jun 23
Departure of Directors or Certain Officers
4:29pm
8-K
SRPT
Sarepta Therapeutics Inc
3 Mar 23
Entry into a Material Definitive Agreement
7:31am
8-K
u7au1h ij3
9 Jan 23
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
1:40pm
8-K
u9adnyp73t6 lnpklp
13 Dec 22
Amendments to Articles of Incorporation or Bylaws
5:11pm
8-K
5o64zk6wftqtuwjo9qtv
2 Nov 22
Departure of Directors or Certain Officers
5:00pm
8-K
pyh7j4enwpo2wnx5749c
19 Sep 22
Entry into a Material Definitive Agreement
4:31pm
8-K
xmxy3 k7k6ddd
3 Jun 22
Departure of Directors or Certain Officers
4:20pm
8-K
gu3wqa784wkkfgyrs
21 Apr 22
Departure of Directors or Certain Officers
8:00am
8-K
ad77uui
5 Apr 22
Departure of Directors or Certain Officers
8:26pm
8-K
9y0j 7sqn
10 Jan 22
Results of Operations and Financial Condition
10:53am
8-K
19svtin4b5kf811slv
17 Nov 21
Departure of Directors or Certain Officers
8:34am
8-K
n7kywhi7
15 Oct 21
Entry into a Material Definitive Agreement
4:17pm
8-K
6tj92 5ljl1q
27 Sep 21
Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful
8:34am
8-K
1l4stw4n
3 Jun 21
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
0ym9pxzk
18 May 21
Regulation FD Disclosure
8:57am
8-K
mwp8k48z1r78w3l
3 May 21
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing
8:52am
8-K
b4pt rwazsgoht7nxy51
11 Jan 21
Results of Operations and Financial Condition
10:32am